Fig. 6
JOSD2 depletion suppresses the growth of patient-derived cells and patient-derived xenografts. a Schematic illustration of patient-derived cell (PDC) and patient-derived xenograft (PDX) models. The schematic diagram was generated from online tools of BioRender (https://app.biorender.com). b Cell proliferation assay in two PDC cells expressing scramble control or JOSD2 shRNA (#1, #2). The PDCs were infected with lentiviruses for 96 h, then these cells were seeded 1000 cells per well in 96-well plates, followed by SRB staining. (means ± SD, n = 3) (means ± SD, n = 3). c, g The in vivo effect of shJOSD2 on PDX model. c Images of mice bearing scramble control and shJOSD2-expressing tumors (top). Images of scramble control and shJOSD2-expressing tumors (bottom) (at the endpoint). d Body weight of each mice in indicated groups (at the endpoint). (mean ± SEM). e Tumor weight of each mice in indicated groups (at the endpoint). (mean ± SEM). f Tumor volume of indicated groups was measured every 2 days (mean ± SEM). g Proteins extracted from PDX tumors of LUAD 083120 were subjected to IB. n.s, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001
